Pfizer opts out of $262M Adolor pain drug pact

Almost exactly three years after Pfizer ($PFE) put up $30 million and a promise of up to $232.5 million to partner on a pair of Adolor's pain programs, the pharma giant has opted to wash its hands of the drugs. Just six months ago Adolor ($ADLR) reported that ADL5859 and ADL5747 failed to clear a mid-stage trial hurdle. And Pfizer told Adolor that further work wasn't warranted, according to a report from Reuters.

After the trial data was released the developer said that an unusually high placebo response was responsible for the clinical setback, another in a long string of disappointments for Pfizer. This has also been a rough year for Adolor. The Exton, PA-based biotech was forced to cut 30 jobs, or about a third of its workforce, last July after sales of Entereg fell behind expactations.

- check out the story from Reuters

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.